Drug Landscape ›
Corticosteroid Topical ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Arthralgia — 1 report (10%) Diarrhoea — 1 report (10%) Dysgraphia — 1 report (10%) Eye Disorder — 1 report (10%) Fatigue — 1 report (10%) Heat Illness — 1 report (10%) Insomnia — 1 report (10%) Musculoskeletal Chest Pain — 1 report (10%) Musculoskeletal Pain — 1 report (10%) Mydriasis — 1 report (10%)
Source database →
Corticosteroid Topical in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Corticosteroid Topical approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Corticosteroid Topical in United States?
University of Sao Paulo is the originator. The local marketing authorisation holder may differ — check the official source linked above.